Advances in therapy for HIV/Hepatitis C virus-coinfected patients in the liver transplant setting

Clinical Infectious Diseases

Volumn 60, Issue 1, 2015, Pages 108-116

  Campos Varela, Isabel ^a   Peters, Marion G ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Direct acting antivirals; Drug drug interaction; Hepatitis C virus; Human immunodeficiency virus; Liver transplant

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; BOCEPREVIR; DACLATASVIR; PARITAPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; FUSED HETEROCYCLIC RINGS; SULFONAMIDE; URIDINE PHOSPHATE;

ANTIVIRAL THERAPY; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIXED INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT INFECTION; SURVIVAL RATE; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPLICATION; HEPATITIS C, CHRONIC; HIV INFECTIONS; PROCEDURES; TRENDS;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; LIVER TRANSPLANTATION; SIMEPREVIR; SOFOSBUVIR; SULFONAMIDES; URIDINE MONOPHOSPHATE;

EID: 84983238434     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu731     Document Type: Article

References (40)

1. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-41.
2. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-17.
3. Terrault NA, Roland ME, Schiano T, et al. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716-26.
4. Miro JM, Montejo M, Castells L, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: A prospective and multicenter cohort study. Am J Transplant 2012; 12:1866-76.
5. Jimenez-Nacher I, Alvarez E, Morello J, Rodriguez-Novoa S, de Andres S, Soriano V. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol 2011; 7:457-77.
6. Coilly A, Roche B, Dumortier J, et al. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: A multicenter experience. J Hepatol 2014; 60:78-86.
7. Frassetto L, Floren L, Barin B, et al. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos 2013; 34:442-51.
8. Barau C, Braun J, Vincent C, et al. Pharmacokinetic study of raltegravir in HIV-infected patients with end-stage liver disease: the LIVERALANRS148 study. Clin Infect Dis 2014; 59:1177-84.
9. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al. All-oral therapywith sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients coinfected with HIV (PHOTON-1). Hepatology 2013; 58(suppl):313A.
10. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
11. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364:2405-16.
12. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34-44.
13. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368:1867-77.
14. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
15. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial. Lancet 2013; 381:2100-7.
16. Lawitz E, Ghalib R, Rodriguez-Torres M, et al. Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype 1 prior null-responder/treatment naive patients (COSMOS study): primary endpoint (SVR12) results in patients with Metavir F3-4 (cohort 2). J Hepatol 2014; 60:S524.
17. Sulkowski M, Pol S, Mallolas J, et al. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: A randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13:597-605.
18. Olysio (package insert). Janssen Products LTN.
19. Everson GT, Terrault NA, Lok AS, et al. A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology 2013; 57:1752-62.
20. Coffin CS, Stock PG, Dove LM, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant 2010; 10:1268-75.
21. Berenguer M. What determines the natural history of recurrent hepatitis C after liver transplantation? J Hepatol 2005; 42:448-56.
22. Berenguer M, Palau A, Aguilera V, Rayon JM, Juan FS, Prieto M. Clinical benefits of antiviral therapy in patients with recurrent hepatitis C following liver transplantation. Am J Transplant 2008; 8:679-87.
23. Carrion JA, Martinez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study. J Hepatol 2009; 50:719-28.
24. Curry MP, Forns X, Chung R, et al. Pretransplant sofosbuvir and ribavirin to prevent recurrence of HCV infection after liver transplantation. Hepatology 2013; 58(suppl):314A.
25. Osinusi A, Meissner EG, Lee YJ, et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial. JAMA 2013; 310:804-11.
26. AASLD/IDSA/IAS-USA. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 10 June 2014.
27. Dieterich D, Rockstroh J, Orkin C, et al. Simeprevir with pegylated interferon/ribavirin in patients co-infected with chronic hepatitis C and HIV-1: week-24 interim analysis of the TMC435-C212 study. In: Program and Abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA, 3-6 March 2013. Abstract 154LB.
28. Miro JM, Montejo M, Blanes M, et al. Outcome of 215 HCV/HIVcoinfected liver transplant recipients: A prospective multicenter study. Top Antiviral Med 2014; 22:S319.
29. Burton JR Jr, O'Leary JG, Verna EC, et al. A US multicenter study of hepatitis C treatment of liver transplant recipients with proteaseinhibitor triple therapy. J Hepatol 2014; 61:508-14.
30. Coilly A, Furlan V, Roche B, et al. Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence. Antimicrob Agents Chemother 2012; 56:5728-34.
31. Terrault N, Reddy KR, Poordad F, et al. Peginterferon and ribavirin for treatment of recurrent hepatitis C disease in HCV-HIV coinfected liver transplant recipients. Am J Transplant 2014; 14:1129-35.
32. Antonini TM, Furlan V, Teicher E, et al. Successful anti-hepatitis C virus therapy with telaprevir in an HIV/hepatitis C virus co-infected patient with a severe recurrence of hepatitis C virus infection on the liver graft. AIDS 2013; 27:2655-7.
33. Alkhouri N, Singh G, Carey WD, et al. The successful use of telaprevir to treat hepatitis C recurrence after liver transplantation in an HIV coinfected patient. Transplantation 2014; 97:e14-5.
34. Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004; 10:868-71.
35. Samuel D, Charlton M, Gane E, et al. Sofosbuvir and ribavirin for the treatment of established recurrent hepatitis C infection after liver transplantation: preliminary results of a prospective multicenter study. J Hepatol 2014; 60:S499.
36. Forns X, Prieto M, Charlton M, et al. Sofosbuvir compassionate use program for patients with severe recurrence hepatitis C including fibrosing cholestatic hepatitis following liver transplantation. J Hepatol 2014; 60: S26.
37. Pellicelli AM, Montalbano M, Lionetti R, et al. Sofosbuvir plus daclatasvir for post-transplant recurrent hepatitis C: potent antiviral activity but no clinical benefit if treatment is given late. Dig Liver Dis 2014; 46:923-7.
38. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl 2012; 18:1053-9.
39. Kwo P, Mantry P, Coakley E, et al. Results of the phase 2 study M12- 999: Interferon-free regimen of ABT-450/R/ABT-267+ABT-333- +ribavirin in liver transplant recipients with recurrent HCV genotype 1 infection. J Hepatol 2014; 60:O114.
40. Aronsohn A, Reau N, Jensen D. Preparing for the uncertain yet inevitable: off label combinations of antiviral agents in HCV. Hepatology 2014; 59(S47):1688-91.